Program
IBI3033
A development code.
Its studies are mostly in Dermatitis, Atopic, led by Innovent Biologics.
Furthest: phase 1, since Dec 16, 20253 company-led studies, 3 open or runningNext primary completion: Feb 10, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 33 open or running | phase 1since Dec 16, 2025 | Dec 16, 2025 | Feb 10, 2027phase 1 · NCT07549984 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 16, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT07311226 · 32 enrolled · China
- Feb 27, 2026Phase 1 study in Healthy ParticipantsNCT07456839 · 8 enrolled · China
- Apr 19, 2026Phase 1 study in Dermatitis, AtopicNCT07549984 · 16 planned · China
Ahead
- Feb 10, 2027Primary completion: phase 1 study in Dermatitis, AtopicNCT07549984
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07549984Dermatitis, Atopic · China | 1 | Not yet recruiting | Feb 10, 2027 | 16 |
| NCT07456839Healthy Participants · China | 1 | Active, not recruiting | Sep 30, 2026 | 8 |
| NCT07311226Healthy Participants · China | 1 | Active, not recruiting | Jun 30, 2026 | 32 |
How it is read
Names in the registry
- “IBI3033”, 3 entries
Codes read as this program: IBI3033.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.